Clinical trial
Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or…
NCT00101192 · Gynecologic Oncology Group, Other · Completed
Key facts
| NCT number | NCT00101192 |
|---|---|
| Title | Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer |
| Official title | A Limited Access Phase II Trial of Cetuximab (C225, NSC #714692) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cervical Cancer |
| Intervention type | Biological, Drug |
| Interventions | cetuximab, cisplatin |
| Enrollment | 76 |
| Start date | Sep 1, 2004 |
| Primary completion | Jul 1, 2011 |
| First posted | Jan 10, 2005 |
| Last update posted | Mar 17, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: